Get the Stockscreener App
2.88
0.69%
-0.02
Jasper Therapeutics Inc stock is traded at $2.88, with a volume of 268.31K.
It is down -0.69% in the last 24 hours and down -49.83% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
See More
Previous Close:
$2.90
Open:
$2.85
24h Volume:
268.31K
Relative Volume:
0.44
Market Cap:
$43.26M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-0.4656
EPS:
-6.1852
Net Cash Flow:
$-52.33M
1W Performance:
-8.57%
1M Performance:
-49.83%
6M Performance:
-52.48%
1Y Performance:
-83.39%
1-Day Range:
$2.81
$2.93
1-Week Range:
$2.81
$3.25
52-Week Range:
$2.265
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
2.88 | 43.56M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-07-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-13-25 | Initiated | UBS | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Sep-09-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-08-24 | Initiated | BTIG Research | Buy |
| Jun-27-24 | Initiated | Stifel | Buy |
| May-06-24 | Initiated | H.C. Wainwright | Buy |
| Apr-03-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-18-24 | Initiated | TD Cowen | Outperform |
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
What catalysts could drive Jasper Therapeutics Inc. stock higher in 2025Stock Market Recommendation With Low Risk - jammulinksnews.com
What are the technical indicators suggesting about Jasper Therapeutics Inc. Equity WarrantStock Strategy Review For Beginners - jammulinksnews.com
Press Release: Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
What is the dividend policy of Jasper Therapeutics Inc. Equity Warrant stockGet ahead with breakthrough trading ideas - jammulinksnews.com
What is Jasper Therapeutics Inc. company’s growth strategyPre Market Picks With High Returns - jammulinksnews.com
Should I hold or sell Jasper Therapeutics Inc. Equity Warrant stock in 2025Top Growth Alerts With Proven Results - jammulinksnews.com
What makes Jasper Therapeutics Inc. stock price move sharplyPost Market Picks With Low Risk - jammulinksnews.com
How does Jasper Therapeutics Inc. Equity Warrant generate profit in a changing economySmart Portfolio Signals To Watch Now - jammulinksnews.com
Is Jasper Therapeutics Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert help - jammulinksnews.com
What is the risk reward ratio of investing in Jasper Therapeutics Inc. stockCapitalize on market trends early - jammulinksnews.com
What are Jasper Therapeutics Inc. Equity Warrant company’s key revenue driversRapidly expanding wealth - jammulinksnews.com
Should I hold or sell Jasper Therapeutics Inc. stock in 2025Free Stock Selection - jammulinksnews.com
Why is Jasper Therapeutics Inc. Equity Warrant stock attracting strong analyst attentionMaximize portfolio value with smart investment plans - jammulinksnews.com
How does Jasper Therapeutics Inc. compare to its industry peersFree Stock Forecasts For 2025 - jammulinksnews.com
What institutional investors are buying Jasper Therapeutics Inc. stockBuild wealth faster with consistent investment plans - jammulinksnews.com
When is Jasper Therapeutics Inc. stock expected to show significant growthFree Market Dynamics Reports - jammulinksnews.com
Does Jasper Therapeutics Inc. Equity Warrant stock perform well during market downturnsMassive wealth growth - jammulinksnews.com
How strong is Jasper Therapeutics Inc. Equity Warrant company’s balance sheetGain access to exclusive stock analysis - jammulinksnews.com
Is Jasper Therapeutics Inc. Equity Warrant stock overvalued or undervaluedFree Stock Market Return Analysis - jammulinksnews.com
What is the dividend policy of Jasper Therapeutics Inc. stockMaximize gains with professional stock picks - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc.JSPR - WV News
Today is July 27 2025 - AInvest
Jasper Therapeutics Inc. Equity Warrant Stock Analysis and ForecastBreakneck growth rates - PrintWeekIndia
When is the best time to buy Jasper Therapeutics Inc. Equity Warrant stockConsistently high yield - jammulinksnews.com
What analysts say about Jasper Therapeutics Inc. Equity Warrant stockFree Stock Market Forecast Reports - Autocar Professional
What drives Jasper Therapeutics Inc. stock priceFree Daily Trading Room Entry - Autocar Professional
Is Jasper Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - jammulinksnews.com
Is Jasper Therapeutics Inc. Equity Warrant a good long term investmentFree Stock Market Return Analysis - jammulinksnews.com
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $29.75 Average Target Price from Analysts - Defense World
Jasper Therapeutics Inc. Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
What drives Jasper Therapeutics Inc. Equity Warrant stock priceFree Market Volatility Navigation Tips - jammulinksnews.com
What analysts say about Jasper Therapeutics Inc. stockMarket-beating performance - jammulinksnews.com
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):